Skip to content

Determinants of Quality Of Life in AGEd Cancer Patients

Assessing the Evolution and Determinants of Quality of Life in Elderly Cancer Patients and Their Caregivers: a Prospective Multicenter Observational Cohort Study.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02672657
Acronym
DEQOLAGE
Enrollment
300
Registered
2016-02-03
Start date
2016-02-29
Completion date
2019-12-31
Last updated
2016-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Neoplasms, Prostatic Neoplasms

Keywords

Health-Related Quality of life, Cancer, Elderly, Caregivers

Brief summary

Patients face multiple stresses and challenges in the aftermath of cancer diagnosis. Despite needs perceived by elderly patients might differ from those of younger patients, there is a paucity of published data assessing the specific evolution and relevant determinants of health-related quality of life (HRQoL) in older patients with cancer. Such determinants may include cancer type/location/stage, treatment type/intensity, comorbidities, nutritional status or socioeconomic features, but also practical organization of care -frequency, geographical distance, supporting measures -, or psychosocial and material support - social network, housing conditions and contextual neighborhood features. Comparatively to dementia or cancer in younger patients, little is known in the oncogeriatric field of the impact on caregivers' perceived burden and HRQol of the support they provide to patients. Further, the potential interactions between patients' and caregivers' HRQoL remain largely unknown, while caregivers are often themselves old with chronic diseases and/or daily living activities' limitations. The DEQOLAGE study is a prospective observational cohort study that aims to describe the HRQoL of patients aged over 70 years with a colorectal or prostatic cancer during the first year following the diagnosis of the disease as well as the HRQoL and burden in their main caregivers. This study will allow a comprehensive assessment of multiple determinants of HRQoL operating at different levels, including individual (cancer type/location/stage, treatment type/intensity, comorbidities, nutritional status or socioeconomic features), contextual (social network, housing conditions and contextual neighborhood features) and organizational factors (frequency, geographical distance, supporting measures). We also hypothesize that complex interactions may operate between patient's and caregiver's HRQoL and perceived burden. Quality of life measurement will be based on two recent scales specifically designed for the elderly to confirm their psychometric properties and in-field feasibility.

Interventions

None listed

Sponsors

Paris 12 Val de Marne University
CollaboratorOTHER
Research Team APEMAC EA4360, University of Lorraine
CollaboratorUNKNOWN
Unité de Recherche Clinique Mondor, Hôpital Henri Mondor
CollaboratorUNKNOWN
Institut de Cancérologie de Lorraine
CollaboratorOTHER
Unité de Coordination en Onco-Gériatrie (UCOG) Sud Val-de-Marne
CollaboratorUNKNOWN
Quality of life and cancer clinical research platform
CollaboratorUNKNOWN
Ligue contre le cancer, France
CollaboratorOTHER
Conseil Régional de Lorraine, France
CollaboratorUNKNOWN
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients Inclusion Criteria: * Aged 70 or more * With a new histologically confirmed diagnosis of colorectal or prostate cancer * With a Comprehensive Geriatric Assessment (CGA) performed before the initiation of cancer treatment * Having expressed their oral non-opposition to participate in the study * Affiliated to a health insurance scheme

Exclusion criteria

* Expected survival inferior to 6 months, based on the clinical appreciation from the physician in charge of the enrollment * Cancer recurrence in patients previously treated * Physical, cognitive or linguistic incapacity to complete questionnaires Caregivers Inclusion criteria * Aged 18 or more * Nonprofessionally, partially or fully helping the patient in daily activities and accompanying the patient to visits; familial ties with the patient are not required (spouse, child, friend or neighbor) * In contact with the patient more than once a week * Defined by the patient during the inclusion visit as the main caregiver

Design outcomes

Primary

MeasureTime frame
Changes in burden of patients' caregivers as assessed by the Zarit burden inventory questionnaireAt baseline, 3, 6, and 12 months
Changes in HRQoL of patients and their caregivers as assessed by the generic WHOQOL-BREF questionnairesAt baseline, 3, 6, and 12 months
Changes in HRQoL of patients and their caregivers if aged >70 years as assessed by the WHOQOL-OLD questionnaireAt baseline, 3, 6, and 12 months
Changes in HRQoL of patients as assessed by the specific EORTC-QLQ C30 questionnaireAt baseline, 3, 6, and 12 months
Changes in HRQoL of patients as assessed by the specific EORTC QLQ-ELD14 questionnaireAt baseline, 3, 6, and 12 months

Secondary

MeasureTime frame
Psychometric properties of the HRQoL questionnaire WHOQOL-OLD (validity, reliability, sensitivity to change, feasibility)At baseline, 3, 6, and 12 months
Psychometric properties of the HRQoL questionnaire EORTC QLQ-ELD14 (validity, reliability, sensitivity to change, feasibility)At baseline, 3, 6, and 12 months
Prognostic value of baseline HRQoL measurements on cancer progression-free survivalAt baseline, 3, 6, and 12 months
Prognostic value of baseline HRQoL measurements on overall survivalAt baseline, 3, 6, and 12 months
Prognostic value of baseline HRQoL measurements on patient's functional decline, defined as any decrease in the ADL scaleAt baseline, 3, 6, and 12 months

Countries

France

Contacts

Primary ContactEtienne Audureau, Md, PhD
etienne.audureau@aphp.fr(0)1 49 81 36 64

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026